KALVISTA PHARMACEUTICALS INC (KALV) Stock Price & Overview
NASDAQ:KALV • US4834971032
Current stock price
The current stock price of KALV is 19.9 USD. Today KALV is up by 0.66%. In the past month the price increased by 22.76%. In the past year, price increased by 85.81%.
KALV Key Statistics
- Market Cap
- 1.006B
- P/E
- N/A
- Fwd P/E
- 23.37
- EPS (TTM)
- -1.90
- Dividend Yield
- N/A
KALV Stock Performance
KALV Stock Chart
KALV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KALV. When comparing the yearly performance of all stocks, KALV is one of the better performing stocks in the market, outperforming 90.69% of all stocks.
KALV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KALV. KALV has a bad profitability rating. Also its financial health evaluation is rather negative.
KALV Earnings
On March 25, 2026 KALV reported an EPS of -0.92 and a revenue of 13.69M. The company missed EPS expectations (-175.71% surprise) and missed revenue expectations (-71.76% surprise).
KALV Forecast & Estimates
15 analysts have analysed KALV and the average price target is 34.68 USD. This implies a price increase of 74.27% is expected in the next year compared to the current price of 19.9.
KALV Groups
Sector & Classification
KALV Financial Highlights
Over the last trailing twelve months KALV reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 47.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.26% | ||
| ROE | -645.16% | ||
| Debt/Equity | 15.81 |
KALV Ownership
KALV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KALV
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Company Info
IPO: 2015-04-09
KALVISTA PHARMACEUTICALS INC
200 Crossing Boulevard
Framingham MASSACHUSETTS 02142 US
CEO: T. Andrew Crockett
Employees: 270
Phone: 18579990075
KALVISTA PHARMACEUTICALS INC / KALV FAQ
Can you describe the business of KALVISTA PHARMACEUTICALS INC?
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
What is the current price of KALV stock?
The current stock price of KALV is 19.9 USD. The price increased by 0.66% in the last trading session.
What is the dividend status of KALVISTA PHARMACEUTICALS INC?
KALV does not pay a dividend.
How is the ChartMill rating for KALVISTA PHARMACEUTICALS INC?
KALV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is KALV stock listed?
KALV stock is listed on the Nasdaq exchange.
Is KALVISTA PHARMACEUTICALS INC (KALV) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KALV.
Can you provide the market cap for KALVISTA PHARMACEUTICALS INC?
KALVISTA PHARMACEUTICALS INC (KALV) has a market capitalization of 1.01B USD. This makes KALV a Small Cap stock.